Applying Evidence to Clinical Practice: 63-Year-Old Patient With R/R MM Post Dara-VRd Induction Scenario

EP: 1.Highlighted Data Review of CAR-T in Early R/R MM

EP: 2.Expert Insights: Distinguishing between CARTITUDE-4 vs. KarMMa-3 Trials

EP: 3.CAR-T in R/R MM: Patient Selection & Treatment Sequencing

EP: 4.CAR-T in Earlier Lines of MM Treatment: Patient Eligibility - Considerations between Ide-cel vs. Cilta-cel

EP: 5.MSKCC Insights: CAR T Referral Process

EP: 6.Overview of the CAR T-Cell Therapy Process: Apheresis, Manufacturing, Potential Bridging Therapies, Lymphodepletion, and Infusion

EP: 7.Collaboration With Community Colleagues: Comanagement and Transitions of Care

EP: 8.CAR T Referral Process: Challenges Seen and How They Can Be Addressed

EP: 9.MSKCC Experiences: Successful CAR T Collaborations With Community and International Providers

EP: 10.CAR-T Clinical Trials: Potentially Moving CAR T Into Earlier Lines of MM Treatment

Now Viewing

EP: 11.Applying Evidence to Clinical Practice: 63-Year-Old Patient With R/R MM Post Dara-VRd Induction Scenario

EP: 12.CAR T in R/R MM: Key Takeaways and Pearls

Video content above is prompted by the following:

• A 68-year-old man with R-ISS II IgG Kappa MM without any high-risk cytogenetic abnormalities diagnosed in June 2024; bone marrow showing 70% abnormal plasma cells, M-spike 4.8, no bone lesions, anemia present. Patient started on Dara-VRd induction by local oncologist, restaging BMBx after 4 cycles showing 60% abnormal plasma cells. Referred to Memorial Sloan Kettering for consideration of salvage treatment +/– autologous stem cell transplantation (ASCT) for refractory disease. After a long discussion with bone marrow transplant team, patient and daughter declined ASCT and requested CAR T referral.

• What is the right time for CAR T referral?
  • High-risk considerations
  • Bridging
  • CAR T product selection
  • Referral process/transition back to community